s
s
s
Develop highly selective and sensitive PK and ADA assays for denosumab (Prolia, Xgeva) using our range of ready-made anti-idiotypic antibodies.
Table 1. Antibodies Specific to Denosumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
---|---|---|---|---|---|---|
Denosumab Inhibitory Type 1 |
HCA288 |
AbD26296 |
Fab-FH1 |
7.1 |
PK bridging ELISA |
|
HCA280 |
AbD26295_hIgG1 |
hIgG1 HRP |
1.8 |
PK bridging ELISA ADA control |
||
HCA281 |
AbD26296_hIgG1 |
hIgG1 |
7.1 |
ADA control |
||
HCA282 |
AbD26862_hIgG1 |
hIgG1 |
0.8 |
ADA control |
||
Denosumab & Denosumab-RANKL Non-Inhibitory Type 2 |
HCA283 |
AbD26781_hIgG1 |
hIgG1 HRP |
19 (Denosumab) |
PK bridging ELISA |
* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags
Type 1 anti-denosumab antibodies inhibit the binding of the drug denosumab to its target, RANKL (receptor activator of nuclear factor kappa-B ligand). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in high, medium and lower affinity, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.
The type 2 anti-denosumab antibody binds to the denosumab idiotope, but does not inhibit the binding of denosumab to RANKL.
Fig. 1. Denosumab PK bridging ELISA using antibodies HCA280 or HCA282 and HCA283P.
Schematic image of PK bridging ELISA with inhibitory (capture) and non-inhibitory (detection) antibodies. Anti-idiotypic capture antibody, Ig format (blue), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format, labeled with HRP.
Fig. 2. Denosumab ADA bridging ELISA using antibody HCA280, HCA281 or HCA282.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.